HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Trial
Phase 2
75
about 1.7 years
18+
10 sites in CA, FL, NV +2
What this study is about
This trial is testing whether a combination of antibodies, TMB-365 and TMB-380, can maintain viral suppression in people with HIV who are no longer taking oral medications. Participants will receive either an infusion of the antibodies every 8 weeks or continue daily oral medication for 48 weeks. Researchers will compare these two approaches to see which one is more effective at keeping the virus under control.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Baseline ART
- 2.Take TMB-365
- 3.Take TMB-380
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
intravenous, oral
Secondary: Pharmacokinetic profile of TMB-365, Pharmacokinetic profile of TMB-380
Immune, Infectious